ADMA Biologics Inc
(NASDAQ:ADMA)
$3.51
-0.05[-1.40%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$3.55
0.0400[1.14%]
Open3.550Close3.510
Vol / Avg.1.075M / 2.147MMkt Cap789.422M
Day Range3.500 - 3.59052 Wk Range2.240 - 4.650

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

ADMA Biologics Stock (NASDAQ:ADMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$11.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.80

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
41000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Raymond James
  • HC Wainwright & Co.
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for ADMA Biologics

All Ratings (17)

Upgrades (1)

Downgrades (0)

Initiations (2)

Q

What is the target price for ADMA Biologics (ADMA)?

A

The latest price target for ADMA Biologics (NASDAQ: ADMA) was reported by Cantor Fitzgerald on August 10, 2023. The analyst firm set a price target for $6.00 expecting ADMA to rise to within 12 months (a possible 70.94% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ADMA Biologics (ADMA)?

A

The latest analyst rating for ADMA Biologics (NASDAQ: ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics maintained their overweight rating.

Q

When is the next analyst rating going to be posted or updated for ADMA Biologics (ADMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating ADMA Biologics (ADMA) correct?

A

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a maintained with a price target of $5.00 to $6.00. The current price ADMA Biologics (ADMA) is trading at is $3.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.